New Targets in the Drug Treatment of Heart Failure.

about

New Targets in the Drug Treatment of Heart Failure.

Item

http://www.wikidata.org/entity/Q38667210

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

New Targets in the Drug Treatment of Heart Failure.

@en

type

Item

label

New Targets in the Drug Treatment of Heart Failure.

@en

prefLabel

New Targets in the Drug Treatment of Heart Failure.

@en

P1476

New Targets in the Drug Treatment of Heart Failure.

@en

P2093

Alan S Maisel

http://www.w3.org/2001/XMLSchema#string

Brian Knight

http://www.w3.org/2001/XMLSchema#string

Danilo Romero

http://www.w3.org/2001/XMLSchema#string

Elizabeth Lee

http://www.w3.org/2001/XMLSchema#string

Fatima Khusro

http://www.w3.org/2001/XMLSchema#string

Hermineh Aramin

http://www.w3.org/2001/XMLSchema#string

James A Iwaz

http://www.w3.org/2001/XMLSchema#string

Matt Kawahara

http://www.w3.org/2001/XMLSchema#string

Minal V Patel

http://www.w3.org/2001/XMLSchema#string

Navaid Iqbal

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines

Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity

Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

Post-acute care: the role of natriuretic peptides

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

Neuregulin as a heart failure therapy and mediator of reverse remodeling

The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction

Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin

P2888

s40265-015-0498-3

P304

187-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-015-0498-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043112203

http://www.w3.org/2001/XMLSchema#string

P698

26659475

http://www.w3.org/2001/XMLSchema#string